GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lisata Therapeutics Inc (FRA:8NE) » Definitions » Research & Development

Lisata Therapeutics (FRA:8NE) Research & Development : €11.83 Mil (TTM As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Lisata Therapeutics Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Lisata Therapeutics's Research & Development for the three months ended in Mar. 2024 was €2.98 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was €11.83 Mil.


Lisata Therapeutics Research & Development Historical Data

The historical data trend for Lisata Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lisata Therapeutics Research & Development Chart

Lisata Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.72 7.61 15.56 41.03 11.68

Lisata Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.97 2.92 3.17 2.76 2.98

Lisata Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €11.83 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lisata Therapeutics  (FRA:8NE) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Lisata Therapeutics Research & Development Related Terms

Thank you for viewing the detailed overview of Lisata Therapeutics's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Lisata Therapeutics (FRA:8NE) Business Description

Traded in Other Exchanges
Address
110 Allen Road, 2nd Floor, Basking Ridge, NJ, USA, 07920
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases.

Lisata Therapeutics (FRA:8NE) Headlines

No Headlines